Second, therapeutic exploration must prioritize testing EEF1A1-targeted strategies—such as small-molecule inhibitors disrupting its STAT1-binding domain or ubiquitination modulators—in humanized SLE models to validate translational potential. This evidence concerns the gene STAT1 and systemic lupus erythematosus.